Evidence map›Paper›PMID 31276481›Full record

ArticlePloS one2019

An exploration of conditions proposed to trigger the Ebola virus glycoprotein for fusion.

Lucie Fénéant, Katarzyna M Szymańska-de Wijs, Elizabeth A Nelson, Judith M White

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A novelMicrobiology spectrum · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lucie FénéantDepartment of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America.
Katarzyna M Szymańska-de WijsDepartment of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America.
Elizabeth A NelsonDepartment of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America.
Judith M WhiteDepartment of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America.ORCID 0000-0002-0532-996X

Funding

Combinations of Approved Drugs to Combat Ebola VirusR01AI114776 · NIAID · UNIVERSITY OF VIRGINIA · PI WHITE, JUDITH M. · 2015 to 2017
$1.5M
NIAID NIH HHS R01 AI114776
6 · The paper itself

Abstract

Ebolaviruses continue to inflict horrific disease and instill fear. The 2013-2016 outbreak in Western Africa caused unfathomable morbidity and mortality (over 11,000 deaths), and the second largest outbreak is on-going in the Democratic Republic of the Congo. The first stage of an Ebolavirus infection is entry, culminating in delivery of the viral genome into the cytoplasm to initiate replication. Among enveloped viruses, Ebolaviruses use a complex entry pathway: they bind to attachment factors on cell surfaces, are engulfed by macropinocytosis, and traffic through the endosomal system. En route, the receptor binding subunit of the glycoprotein (GP) is reduced from ~130 to ~19 kDa by cathepsins. This event allows cleaved GP (GPcl) to bind to Niemann-Pick C1 (NPC1), its endosomal receptor. The virus then fuses with a late endosomal membrane, but how this occurs remains a subject of debate. An early, but standing, observation is that entry of particles bearing GPcl is inhibited by agents that raise endosomal pH or inhibit cysteine proteases, suggesting the need for an additional factor(s). Yet, some have concluded that NPC1 is sufficient to trigger the fusion activity of GPcl. Here, we re-examined this question using sensitive cell-cell and pseudovirus-cell fusion assays. We did not observe detectable GPcl-mediated fusion with NPC1 or its GPcl binding domain at any pH tested, while robust fusion was consistently observed with GP from lymphocytic choriomeningitis virus at low pH. Addition of proposed fusion-enhancing factors-cations (Ca++ and K+), a reducing agent, the anionic lipid Bis(Monoacylglycero)Phosphate, and a mixture of cathepsins B and L-did not induce detectable fusion. Our findings are in line with the earlier proposal that an additional factor is required to trigger the full fusion activity of GPcl after binding to NPC1. We discuss caveats to our study and what the missing factor(s) might be.

Indexed as

AnimalsCarrier ProteinsCell FusionCell LineEbolavirusHemorrhagic Fever, EbolaHumansNiemann-Pick C1 ProteinProtein BindingReceptors, VirusViral Envelope ProteinsViral Fusion ProteinsCarrier ProteinsNiemann-Pick C1 ProteinReceptors, VirusViral Envelope ProteinsViral Fusion Proteins

Identifiers

PMID31276481
PMCPMC6611598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.